Experimental Therapeutics Program
Overview | Leaders | Research | Publications | Resources | Members
Selected Publications
2004
Akula N, Bhalla J, Sridhar J, Pattabiraman N. Binding modes of 6,7 di-substituted 4-anilinoquinoline-3-carbonitriles to EGFR. Bioorg Med Chem Lett 2004;14(13):3397-3400.
Asatiani E, Cohen P, Ozdemirli M, Kessler CM, Mavromatis B, Cheson BD. Monoclonal gammopathy in extranoodal marginal zone lymphoma (ENMZL) correlates with advanced disease and bone marrow involvement. Am J Hematol 2004;77(2):144-6.
Bennett TN, Paguio M, Gligorijevic B, Seudieu C, Kosar AD, Davidson E, Roepe PD. Novel, rapid, and inexpensive cell-based quantification of antimalarial drug efficacy. Antimicrob Agents Chemother 2004;48(5):1807-1810.
Bennett TN, Kosar AD, Ursos LM, Dzekunov S, Singh Sidhu AB, Fidock DA, Roepe PD. Drug resistance-associated pfCRT mutations confer decreased Plasmodium falciparum digestive vacuolar pH. Mol Biochem Parasitol 2004;133(1):99-114.
Cernak I, Vink R, Zapple DN, Cruz MI, Ahmed F, Chang T, Fricke ST, Faden AI. The pathobiology of moderate diffuse traumatic brain injury as identified using a new experimental model of injury in rats. Neurobiol Dis 2004;17(1):29-43.
Cernak I, Vink R, Natale J, Stoica B, Lea PM, Movsesyan V, Ahmed F, Knoblach SM, Fricke ST, Faden AI. The "dark side" of endocannabinoids: a neurotoxic role for anandamide. J Cereb Blood Flow Metab 2004;24(5):564-578.
de Dios AC, Casabianca LB, Kosar A, Roepe PD. Structure of the amodiaquine-FPIX mu oxo dimer solution complex at atomic resolution. Inorg Chem 2004;43(25):8078-8084.
Faden AI, Knoblach SM, Movsesyan VA, Cernak I. Novel small peptides with neuroprotective and nootropic properties. J Alzheimers Dis 2004;6(6 Suppl):S93-S97.
Fricke ST, Vink R, Chiodo C, Cernak I, Ileva L, Faden AI. Consistent and reproducible slice selection in rodent brain using a novel stereotaxic device for MRI. J Neurosci Methods 2004;136(1):99-102.
Gaskin DJ, Weinfurt KP, Castel LD, DePuy V, Li Y, Balshem A, Benson A, Burnett CB, Corbett S, Marshall J, Slater E, Sulmasy DP, Van Echo D, Meropol NJ, Schulman KA. An exploration of relative health stock in advanced cancer patients. Med Decis Making 2004;24(6):614-624.
Jhaveri MS, Rait AS, Chung KN, Trepel JB, Chang EH. Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment. Mol Cancer Ther 2004;3(12):1505-1512.
Knoblach SM, Alroy DA, Nikolaeva M, Cernak I, Stoica BA, Faden AI. Caspase inhibitor z-DEVD-fmk attenuates calpain and necrotic cell death in vitro and after traumatic brain injury. J Cereb Blood Flow Metab 2004;24(10):1119-1132.
Levy B, Panicalli D, Marshall J. TRICOM: enhanced vaccines as anticancer therapy. Expert Rev Vaccines 2004;3(4):397-402.
Liu MC, Marshall JL, Pestell RG. Novel strategies in cancer therapeutics: targeting enzymes involved in cell cycle regulation and cellular proliferation. Curr Cancer Drug Targets 2004;4(5):403-424.
Mandal AK, Zhang Z, Ray R, Choi MS, Chowdhury B, Pattabiraman N, Mukherjee AB. Uteroglobin represses allergen-induced inflammatory response by blocking PGD2 receptor-mediated functions. J Exp Med 2004;199(10):1317-1330.
 Marshall J, Chen H, Yang D, Figueira M, Bouker KB, Ling Y, Lippman M, Frankel SR, Hayes DF. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol 2004;15(8):1274-1283.
Marshall JL, Eisenberg SG, Johnson MD, Hanfelt J, Dorr FA, El Ashry D, Oberst M, Fuxman Y, Holmlund J, Malik S. A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2004;4(4):268-274.
Moroni M, Soldatenkov V, Zhang L, Zhang Y, Stoica G, Gehan E, Rashidi B, Singh B, Ozdemirli M, Mueller SC. Progressive loss of Syk and abnormal proliferation in breast cancer cells. Cancer Res 2004; 64(20):7346-7354.
Movsesyan VA, Stoica BA, Faden AI. MGLuR5 activation reduces beta-amyloid-induced cell death in primary neuronal cultures and attenuates translocation of cytochrome c and apoptosis-inducing factor. J Neurochem 2004;89(6):1528-1536.
Movsesyan VA, Stoica BA, Yakovlev AG, Knoblach SM, Lea PM, Cernak I, Vink R, Faden AI. Anandamide-induced cell death in primary neuronal cultures: role of calpain and caspase pathways. Cell Death Differ 2004;11(10):1121-1132.
Oh A, List HJ, Reiter R, Mani A, Zhang Y, Gehan E, Wellstein A, Riegel AT. The nuclear receptor coactivator AIB1 mediates insulin-like growth factor I-induced phenotypic changes in human breast cancer cells. Cancer Res 2004;64(22):8299-8308.
Ozdemirli M, Cheson B, Jaffe ES. What is anaplastic large cell lymphoma? Am J Surg Pathol 2004;28(12):1664-1665.
Pei XF, Noble MS, Davoli MA, Rosfjord E, Tilli MT, Furth PA, Russell R, Johnson MD, Dickson RB. Explant-cell culture of primary mammary tumors from MMTV-c-Myc transgenic mice. In Vitro Cell Dev Bio Anim 2004;40(1-2):14-21.
Rajnarayanan RV, Dakshanamurthy S, Pattabiraman N. "Teaching old drugs to kill new bugs": structure-based discovery of anti-SARS drugs. Biochem Biophys Res Commun 2004;321(2):370-378.
Rizvi NA, Humphrey JS, Ness EA, Johnson MD, Gupta E, Williams K, Daly DJ, Sonnichsen D, Conway D, Marshall J, Hurwitz H. A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin Cancer Res 2004;10(6):1963-1970.
Rudin CM, Marshall JL, Huang CH, Kindler HL, Zhang C, Kumar D, Gokhale PC, Steinberg J, Wanaski S, Kasid UN, Ratain MJ. Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin Cancer Res 2004;10(21):7244-7251.
Sun H, Nikolovska-Coleska Z, Yang CY, Xu L, Liu M, Tomita Y, Pan H, Yoshioka Y, Krajewski K, Roller PP, Wang S. Structure-based design of potent, conformationally constrained Smac mimetics. J Am Chem Soc 2004;126(51):16686-16687.
Toretsky J, Levenson A, Weinberg IN, Tait JF, Uren A, Mease RC. Preparation of F-18 labeled annexin V: a potential PET radiopharmaceutical for imaging cell death. Nucl Med Biol 2004;31(6):747-752.
Uren A, Wolf V, Sun YF, Azari A, Rubin JS, Toretsky JA. Wnt/Frizzled signaling in Ewing sarcoma. Pediatr Blood Cancer 2004;43(3):243-249.
Uren A, Tcherkasskaya O, Toretsky JA. Recombinant EWS-FLI1 oncoprotein activates transcription. Biochemistry 2004;43(42):13579-13589.
Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun JA, Marshall JL, Mitchell EP, Perez-Manga G, Rougier P, Schmiegel W, Schoelmerich J, Sobrero A, Schilsky RL. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004;90(6):1190-1197.
Williams ML, Torres-Duarte A, Brant LJ, Bhargava P, Marshall J, Wainer IW. The relationship between a urinary cachectic factor and weight loss in advanced cancer patients. Cancer Invest 2004;22(6):866-870.
Yakovlev AG, Di Giovanni S, Wang G, Liu W, Stoica B, Faden AI. BOK and NOXA are essential mediators of p53-dependent apoptosis. J Biol Chem 2004;279(27):28367-28374.
Yakovlev AG, Faden AI. Mechanisms of neural cell death: implications for development of neuroprotective treatment strategies. NeuroRx 2004;1(1):5-16.
Yu W, Pirollo KF, Yu B, Rait A, Xiang L, Huang W, Zhou Q, Ertem G, Chang EH. Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. Nucleic Acids Res 2004;32(5):e48.
Yu W, Pirollo KF, Rait A, Yu B, Xiang LM, Huang WQ, Zhou Q, Ertem G, Chang EH. A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene. Gene Ther 2004;11(19):1434-1440.
Zhang H, Paguio M, Roepe PD. The antimalarial drug resistance protein Plasmodium falciparum chloroquine resistance transporter binds chloroquine. Biochemistry 2004;43(26):8290-8296.
Zhang Y, Glass A, Bennett N, Oyama KA, Gehan E, Gelmann EP. Long-term outcomes after radical prostatectomy performed in a community-based health maintenance organization. Cancer 2004;100(2):300-307.
Beagles K, Wellstein A, Bayer B. Systemic morphine administration suppresses genes involved in antigen presentation. Mol Pharmacol 2004;65(2):437-442.
Burbelo P, Wellstein A, and Pestell RG. Altered Rho GTPase signaling pathways in breast cancer cells. Breast Cancer Res Treat 2004;84:43-48.
D'Amico M, Wu K, Fu M, Rao M, Albanese C, Russell RG, Lian H, Bregman D, White MA, and Pestell RG. The inhibitor of cyclin-dependent kinase 4a/alternative reading frame (INK4a/ARF) locus encoded proteins p16INK4a and p19ARF repress cyclin D1 transcription through distinct cis elements. Cancer Res 2004;64:4122-4130.
Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M, Hurley C, Kollman C, Anasetti C, Noreen H, Begovich A, Hildebrand W, Petersdorf E, Schmeckpeper B, Setterholm M, Trachtenberg E, Williams T, Yunis E, Weisdorf D. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004;104(7):1923-1930.
Henke RT, Haddad BR, Kim SE, Rone JD, Mani A, Jessup JM, Wellstein A, Maitra A, Riegel AT. Overexpression of the nuclear receptor coactivator AIB1 (SRC-3) during progression of pancreatic adenocarcinoma. Clin Cancer Res 2004;10(18 Pt 1):6134-6142.
Hulit J, Wang C, Li Z, Albanese C, Rao M, Di Vizio D, Shah S, Byers SW, Mahmood R, Augenlicht LH, Russell R, Pestell RG. Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice. Mol Cell Biol 2004;24(17):7598-7611.
Jessup JM, Samara R, Battle P, Laguinge LM. Carcinoembryonic antigen promotes tumor cell survival in liver through an IL-10-dependent pathway. Clin. Exp. Metastasis. 2004;21:709-17.
Jessup JM, Laguinge LM, S. Lin S, Samara R, Aufman K, Battle P, Frantz M, Edmiston KH, Thomas P. Carcinoembryonic antigen induction of IL-10 and IL-6 inhibits hepatic ischemic/reperfusion injury to colorectal carcinoma cells. Int. J. Cancer 2004;111:332-337.
Kurtz A, Aigner A, Cabal-Manzano RH, Butler RE, Hood DR, Sessions RB, Czubayko F, and Wellstein A. Differential Regulation of a Fibroblast Growth Factor-Binding Protein during Skin Carcinogenesis and Wound Healing. Neoplasia 2004;6:595-602.
Laguinge LM, Lin S, Samara RN, Salesiotis AN, Jessup JM. Nitrosative Stress in Rotated Three-Dimensional Colorectal Carcinoma Cell Cultures Induces Microtubule Depolymerization and Apoptosis. Cancer Res 2004;64(8):2643-8.
Levy B, Panicalli D, and Marshall J. TRICOM: enhanced vaccines as anticancer therapy. Expert Rev Vaccines 2004;3:397-402.
Liu N, Xu XM, Chen J, Wang L, Yang S, Underhill CB, and Zhang L. Hyaluronan-binding peptide can inhibit tumor growth by interacting with Bcl-2. Int J Cancer 2004;109:49-57.
Marshall J, Chen H, Yang D, Figueira M, Bouker KB, Ling Y, Lippman M, Frankel SR, and Hayes DF. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol 2004;15:1274-1283.
Milinkovic M, Antin JH, Hergrueter CA, Underhill CB, and Sackstein R. CD44-hyaluronic acid interactions mediate shear-resistant binding of lymphocytes to dermal endothelium in acute cutaneous GVHD. Blood 2004;103:740-742.
Mishra B, Tang Y, Katuri V, Fleury T, Said AH, Rashid A, Jogunoori W, and Mishra L. Loss of cooperative function of transforming growth factor-beta signaling proteins, smad3 with embryonic liver fodrin, a betaspectrin, in primary biliary cirrhosis. Liver Int 2004;24:637-645.
Moroni M, Soldatenkov V, Zhang L, Zhang Y, Stoica G, Gehan E, Rashidi B, Singh B, Ozdemirli M, and Mueller SC. Progressive loss of Syk and abnormal proliferation in breast cancer cells. Cancer Res 2004;64:7346-7354.
Oh A, List HJ, Reiter R, Mani A, Zhang Y, Gehan E, Wellstein A, and Riegel AT. The Nuclear Receptor Coactivator AIB1 Mediates Insulin-like Growth Factor I-induced Phenotypic Changes in Human Breast Cancer Cells. Cancer Res 2004;64:8299-8308.
Peck JW, Bowden ET, and Burbelo PD. Structure and function of human Vps20 and Snf7 proteins. Biochem J 2004;377:693-700.
Pei XF, Noble MS, Davoli MA, Rosfjord E, Tilli MT, Furth PA, Russell R, Johnson MD, and Dickson RB. Explant-cell culture of primary mammary tumors from MMTV-c-Myc transgenic mice. In Vitro Cell Dev Biol Anim 2004;40:14-21.
Reiter R, Oh AS, Wellstein A, and Riegel AT. Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity. Oncogene 2004;23:403-409.
Rizvi NA, Humphrey JS, Ness EA, Johnson MD, Gupta E, Williams K, Daly DJ, Sonnichsen D, Conway D, Marshall J, Hurwitz H. A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin Cancer Res 2004;10:1963-1970.
Russell RG, Lasorella A, Dettin LE, and Lavarone A. Id2 drives differentiation and suppresses tumor formation in the intestinal epithelium. Cancer Res 2004;64:7220-7225.
Zhou X, Stuart A, Dettin LE, Rodriguez G, Hoel B, and Gallicano GI. Desmoplakin is required for microvascular tube formation in culture. J Cell Sci 2004;117:3129-3140.
